NCT03622541 Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD Status COMPLETED Phase PHASE2
NCT03585517 Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) Status COMPLETED Phase PHASE1
NCT03466320 DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Status COMPLETED Phase PHASE1/PHASE2
NCT03465540 Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies Status TERMINATED Phase PHASE1
NCT03459859 Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS Status COMPLETED Phase PHASE1
NCT03315299 Individual Patient Expanded Access Gilteritinib (ASP2215) Status NO_LONGER_AVAILABLE Phase N/A
NCT03275636 Haploidentical Donor vs mMUD in Hematological Malignancies Status COMPLETED Phase PHASE2/PHASE3
NCT03170895 Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD Status COMPLETED Phase PHASE2
NCT03138395 iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML Status WITHDRAWN Phase N/A
NCT03135054 Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD Status UNKNOWN Phase PHASE2
NCT03118466 Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Status COMPLETED Phase PHASE2
NCT03031262 Efficacy and Safety of Chidamide in CBF Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03031249 Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia Status ENROLLING_BY_INVITATION Phase PHASE1/PHASE2
NCT03021330 Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML Status ACTIVE_NOT_RECRUITING Phase PHASE3